In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.
作者信息
Sun Qiu N, Najvar Laura K, Bocanegra Rosie, Loebenberg David, Graybill John R
机构信息
Division of Infectious Disease, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, USA.
出版信息
Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2. doi: 10.1128/AAC.46.7.2310-2312.2002.
Abstract
The in vivo activities of posaconazole, itraconazole, and amphotericin B in neutropenic mice with zygomycosis were compared. The in vitro MICs of posaconazole and itraconazole for the strains of Mucor spp. used in this study ranged from 0.125 to 8 microg/ml and 0.25 to 8 microg/ml, respectively. The in vitro MIC range for amphotericin B is 0.125 to 0.25 microg/ml. At twice-daily doses of >or=15 mg/kg of body weight, posaconazole prolonged the survival of the mice and reduced tissue burden.
摘要
相似文献
1
In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.
Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2. doi: 10.1128/AAC.46.7.2310-2312.2002.
2
In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.
Antimicrob Agents Chemother. 2012 May;56(5):2246-50. doi: 10.1128/AAC.05956-11. Epub 2012 Jan 30.
3
Drug combinations against Mucor irregularis in vitro.
Antimicrob Agents Chemother. 2013 Jul;57(7):3395-7. doi: 10.1128/AAC.02612-12. Epub 2013 Apr 15.
4
A Revised Species Concept for Opportunistic Species Reveals Species-Specific Antifungal Susceptibility Profiles.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00653-19. Print 2019 Aug.
5
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.
6
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Antimicrob Agents Chemother. 2002 Apr;46(4):1032-7. doi: 10.1128/AAC.46.4.1032-1037.2002.
7
Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Med Mycol. 2008 Sep;46(6):567-73. doi: 10.1080/13693780801975576.
8
Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
J Antimicrob Chemother. 2017 Feb;72(2):462-466. doi: 10.1093/jac/dkw433. Epub 2016 Oct 24.
9
Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.
Antimicrob Agents Chemother. 2015 Mar;59(3):1745-50. doi: 10.1128/AAC.04435-14. Epub 2015 Jan 12.
10
Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment.
Med Mycol. 2019 Apr 1;57(3):351-362. doi: 10.1093/mmy/myy042.
引用本文的文献
1
Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.
Eur J Med Chem. 2023 Jan 15;246:115010. doi: 10.1016/j.ejmech.2022.115010. Epub 2022 Dec 10.
2
Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis.
J Fungi (Basel). 2021 Apr 18;7(4):313. doi: 10.3390/jof7040313.
3
High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.
Mycoses. 2020 Feb;63(2):122-130. doi: 10.1111/myc.13028. Epub 2019 Dec 15.
4
Posaconazole: An Update of Its Clinical Use.
Pharmacy (Basel). 2015 Oct 21;3(4):210-268. doi: 10.3390/pharmacy3040210.
5
Facial nerve paralysis: A case report of rare complication in uncontrolled diabetic patient with mucormycosis.
J Nat Sci Biol Med. 2015 Jan-Jun;6(1):226-8. doi: 10.4103/0976-9668.149195.
6
Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.
Antimicrob Agents Chemother. 2015 Mar;59(3):1745-50. doi: 10.1128/AAC.04435-14. Epub 2015 Jan 12.
7
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.
8
Mucormycosis in an HIV-infected renal transplant patient: A case report and review of the literature.
Am J Case Rep. 2014 Feb 15;15:74-8. doi: 10.12659/AJCR.890026. eCollection 2014.
9
Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient.
Ecancermedicalscience. 2013 Dec 19;7:382. doi: 10.3332/ecancer.2013.382. eCollection 2013.
10
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.
Infect Drug Resist. 2013 Oct 22;6:163-74. doi: 10.2147/IDR.S51340.
本文引用的文献
1
Phycomycosis. A clinicopathologic study of fifty-one cases.
Lab Invest. 1962 Nov;11:963-85.
2
In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole.
J Antimicrob Chemother. 2001 Dec;48(6):919-21. doi: 10.1093/jac/48.6.919.
3
Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole.
J Antimicrob Chemother. 2001 Oct;48(4):583-6. doi: 10.1093/jac/48.4.583.
4
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion.
Eur J Clin Microbiol Infect Dis. 2001 Jul;20(7):460-6. doi: 10.1007/s100960100528.
5
Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients.
Clin Infect Dis. 2000 Oct;31(4):910-3. doi: 10.1086/318144. Epub 2000 Oct 11.
6
Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients.
Mycoses. 1999;42 Suppl 2:97-100.
7
Zygomycosis in the 1990s in a tertiary-care cancer center.
Clin Infect Dis. 2000 Jun;30(6):851-6. doi: 10.1086/313803. Epub 2000 Jun 13.
8
Zygomycetes in human disease.
Clin Microbiol Rev. 2000 Apr;13(2):236-301. doi: 10.1128/CMR.13.2.236.
9
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
J Clin Microbiol. 1998 Oct;36(10):2950-6. doi: 10.1128/JCM.36.10.2950-2956.1998.
10
Rhinocerebral zygomycosis.
Mycoses. 1998 Jan-Feb;41(1-2):51-3. doi: 10.1111/j.1439-0507.1998.tb00376.x.
Zotero 插件